Abstract While cardiac troponins (cTnT and cTnI) have been used as blood biomarkers of myocardial injury such as myocardial infarction in both humans and animals, their high diagnostic sensitivity inevitably leads to decreased diagnostic specificity. For example, it is difficult to judge whether a slight increase of cardiac troponins in toxicological studies is a treatment-related response or not. Drawing an accurate conclusion requires reliable background data and definitive criteria based on that data. However, no organized efforts in setting such criteria has been reported. Here, we measured blood cTnI and cTnT concentrations in Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys from repeated blood samplings using needle cylinders under restraint up until 24 h after a single oral dose of 0.5 w/v% methyl cellulose solution as a vehicle. We revealed the extent of individual differences in baseline levels and operational effects. Our results can be useful in making criteria for judgment of treatment-related changes in cardiac troponins.
Introduction
Cardiac troponins (cTnT and cTnI) are used as clinical blood biomarkers for myocardial injuries such as myocardial infarction (Mahajan and Jarolim 2011) since they have high diagnostic sensitivity and tissue specificity. Since their structure and function are highly conserved across species (O'Brien et al. 2006) , cardiac troponins are also used as translational biomarkers in experimental studies in animals (Berridge et al. 2009; Hausner et al. 2013; Herman et al. 2001; Newby et al. 2011; Pierson et al. 2013; Undhad et al. 2012) . However, despite the usability of troponins in cardiac injuries, their high diagnostic sensitivity still poses a challenge since increased diagnostic sensitivity inevitably results in decreased diagnostic specificity (i.e., an increased number of false positives) (Mahajan and Jarolim 2011) . In particular, when they are applied in toxicological studies, it is often difficult to distinguish treatment-related changes from operational changes. Therefore, obtaining data about blood cardiac troponin levels in intact animals is extremely important.
Schultze et al. previously reported blood cTnI measurements in intact Sprague-Dawley rats and cynomolgus monkeys. Their experiments consisted of careful measurements made over multiple time points under resting conditions after saline administration by oral gavage (Schultze et al. 2009 (Schultze et al. , 2015 . Although these studies provided much-needed data for future cTnI research, serial blood samplings were conducted using an automated cannulation method, which is different from the standard procedures of most toxicity studies (i.e., repeated needle injections under restraint).
Here, we aimed to obtain background data in a setting similar to that of typical pharmaceutical toxicological studies conducted in animals. We measured blood cTnI and cTnT concentrations in Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys, from repeated blood samplings using needle cylinders under restraint up until 24 h after a single oral dose of 0.5 w/v% methyl cellulose solution as vehicle. In addition, for dogs and cynomolgus monkeys, we also measured creatine kinase (CK) and lactate dehydrogenase (LDH) to monitor the extent of struggle during the restraint.
Material and methods

Animals experiments
Rats Seven-week-old male and female Sprague-Dawley rats (Crl:CD (SD)) supplied from Charles River Japan Inc. (Tokyo, Japan) were used. Animals were kept in bracket-type stainless steel wire-meshed cages (two or three animals per cage during the study period) at a temperature of 23 ± 3°C and relative humidity of 55 ± 15% with illumination of 12 h per day from 7 a.m. to 7 p.m. Animals could freely access CRF-1 pellet diet (Oriental Yeast Co., Ltd. (Tokyo, Japan)) and drinking water. Animals were quarantined and acclimated for 2 weeks. Five male and female animals were treated with a single oral dose of 0.5 w/v% methyl cellulose solution (5 mL/kg) using flexible stomach tubes and syringes. Around 0.25 mL/animal of blood was collected via tail vein while conscious and restrained at 0.5, 1, 2, 4, and 8 h after the treatment. In addition, around 2 mL/animal of blood was collected via the abdominal aorta under anesthesia with isoflurane 24 h after the treatment. Blood samples collected in sodium heparin tubes were immediately placed on ice, centrifuged by 10,000 rpm at 4°C for 2 min to obtain plasma, and stored at − 80°C until measurement.
Dogs Ten-to 13-month-old male and female beagle dogs that had been supplied from Hongo Farm, Kitayama Labes Co., Ltd. (Yamaguchi, Japan) were used. Animals were kept in stainless cages (one animal per cage) under the temperature of 23 ± 3°C and relative humidity of 50 ± 20% with illumination of 12 h per day from 7 a.m. to 7 p.m. Animals were supplied with around 300 g/day of NVE-10 pellet diet (Nihon Pet Food (Tokyo, Japan)) and could freely access to and drinking water. Animals were acclimated to the test condition for 2 weeks, during which the animals were treated with drinking water (30 mL/animal) in the same manner as methyl cellulose solution. After that, 30 male and 30 female animals were treated with a single oral dose of 0.5 w/v% methyl cellulose solution (5 mL/kg) using disposable catheter and syringe. Around 7.8 (only at − D6) or 2.3 mL/animal per timepoint (0.3 mL for cTnT and 2 mL for the other items) of blood was collected via external jugular vein from conscious animals 6 days before the treatment (− D6) and just before (Pre) and 0.5, 1, 2, 4, 8, and 24 h after the treatment (D0). For the cTnT measurement, blood samples collected in sodium heparin tubes were immediately placed on ice until measurement. For the measurements of the other parameters, collected blood samples were placed at room temperature for 20-60 min, centrifuged (room temperature, 3000 rpm for 10 min) to obtain serum, and either measured within the same day or stored at −70°C until measurement.
Cynomolgus monkeys Three-to seven-year-old male and female cynomolgus monkeys that had been supplied from Angkor Primates Center Inc. (Kampong Thom, Cambodia) or Tian Hu Cambodia Animal Breeding Research Center Ltd. (Kampong Thom, Cambodia) were used. Animals were kept in stainless cages (one animal per cage) at a temperature of 26 ± 3°C and relative humidity of 50 ± 20% with illumination of 12 h per day from 7 a.m. to 7 p.m. Animals were supplied with around 108 g/animal/day of HF Primate J 12G pellet diet (Purina Mills, LLC. (MO, USA)) and could freely access to drinking water. Animals were acclimated to the test conditions for 2 weeks, during which the animals were treated with drinking water (10 mL/animal) in the same manner as methyl cellulose solution. After that, 10 male and 10 female animals were treated with a single oral dose of 0.5 w/v% methyl cellulose solution (5 mL/kg) using disposable catheters and syringes. Around 4.5 (only at − D13) or 2.3 mL/animal per time point (0.3 mL for cTnT and 2 mL for the other items) of blood was collected via femoral vein under unanesthetized condition and restraint in a restraint device 13 days before the treatment (− D13) and just before (Pre) and 0.5, 1, 2, 4, 8, and 24 h after the treatment (D0). For the cTnT measurement, blood samples collected in sodium heparin tubes were immediately placed on ice until measurement. For the parameters of the other items, collected blood samples were placed at room temperature for 20-60 min, centrifuged (room temperature, 3000 rpm for 10 min) to obtain serum, and either measured within the same day or stored at − 80°C until measurement.
Dosing formulation
The requisite amount of methyl cellulose (Metlose® SM-400, Shin-Etsu Chemical Co., Ltd., Tokyo, Japan) was dissolved in water for injection (Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan.) to make a concentration of 0.5 w/v%.
Clinical testing methods
cTnI and cTnT levels were measured in rats, dogs and cynomolgus monkeys. CK and LDH levels were also measured in dogs and monkeys to monitor the effect by strenuous movement. The measurement methods are as follows. Note that all the testing methods were validated for their intra-assay precision, inter-assay precision, and frozen stability.
Results
None of the study animals exhibited an abnormal general condition.
Rats
Plasma cTnI levels were below the lower limit of quantification (BLOQ) at almost all time points except for in one male (RM05) and two females (RF01 and RF02) 2 h after dosing, and one male (RM05) 4 h after dosing (Table 1 ). The detected levels were from 0.015 to 0.028 ng/mL. All time points for plasma cTnT levels were BLOQ (Table 1) .
Dogs
Serum cTnI levels were detected in almost all animals except for in 2 males (DM22 and DM27) ( Table 2) . Although the levels detected varied among individuals, a tendency for levels to be constant throughout the examination period was noted in animals that showed higher levels (DM12). For blood cTnT levels, one male (DM26) and five females (DF03, DF13, DF22, DF28, and DF29) showed detectable but lower levels throughout the examination period (Table 2 ). The other animals showed BLOQ at all points.
No animals showed abnormal LDH values throughout the examination period (Table 2) . One male (DM13 and DM23) and two females (DF15 and DF16) showed higher CK values 8 h after dosing than those at pre-dosing (Table 2) . No corresponding change to higher CK values were noted in cTnI or cTnT in these animals. 
Mean 0.000 0.000 0.000 0.000 0.000 0.000 SD 0.000 0.000 0.000 0.000 0.000 0.000 cTnI measurements in female rats cTnI (ng/mL) 
Mean 0.000 0.000 0.000 0.000 0.000 0.000 SD 0.000 0.000 0.000 0.000 0.000 0.000 cTnI: Values below the lower limit of quantification (BLOQ) (0.010 ng/mL) were shown as B-^and regarded as 0 ng/mL in calculation cTnT: Values below the lower limit of quantification (BLOQ) (0.392 to 0.412 ng/mL) were shown as B-^and regarded as 0 ng/mL in calculation No. − Pre 0.5h 1h 2h 4h 8h 24h 
Cynomolgus monkey
One female (CF01) showed a higher level of serum cTnI at all points (Table 3) . Three males (CM02, CM04, and CM08) and one female (CF09) showed sporadically low levels of cTnI through the examination period (Table 3) . Only two males (CM07 and CM08) showed low but detectable blood cTnT values (Table 3) . Although the higher levels of CK or LDH were detected sporadically, no correspondences were noted in the changes in cTnI or cTnT levels (Table 3) . DF20 110  66  48  45  65  93  90  69  DF21 47  53  57  60  154 57  54  69  DF22 41  125 39  43  82  68  37  44  DF23 49  43  72  48  43  63  44  45  DF24 54  87  113  57  50  72  49  71  DF25 54  47  100  43  123 122 34  83  DF26 39  53  42  33  60  52  44  42  DF27 51  51  43  63  38  76  42  45  DF28 75  81  53  46  41  56  33  61  DF29 63  162 66  58  51  54  50  69  DF30 41  40  127  95  52  70  41  46  Mean 59  69  59  50  60  72  64  69  SD  18  31  21  12  28  22  23 No. − Pre 0.5h 1h 2h 4h 8h 24h 
Discussion
In this study, we revealed the extent of individual differences in baseline levels and operational effects in Sprague Dawley rats, beagle dogs, and cynomolgus monkeys from repeated blood samplings using needle cylinders under restraint up until 24 h after a single oral dose of 0.5 w/v% methyl cellulose solution as a vehicle. For the rats, although some animals showed temporal elevations 2-4 h after dosing, cTnI levels were BLOQ at almost all examination points. In contrast, there were substantially larger individual differences in baseline levels of cTnI in dogs (greater than 20-fold) and cynomolgus monkeys (greater than 5-fold). cTnI values fluctuated around individual baselines without clear correlations in timing or with CK and LDH elevations seen in some animals. This suggests that these fluctuations of cTnI values were not caused by the experimental procedures, neither treatment nor operational, and thus individual variations in baseline levels need to be taken into account when evaluating cTnI levels in blood collected. Based on these results, we propose the criteria shown here: For rats, we can evaluate cTnI levels from blood sampling 24 h after treatment by simply adopting the BLOQ as a criterion for treatment-related effects (e.g., compoundinduced effects after drug administration), without needing to consider individual variations or operational effects. When we evaluate cTnI levels from blood sampling collected periodically within the same day of treatment, however, we need to reject temporal elevations as operational effects, based on historical background data defined at each facility (e.g., 0.02 ng/mL, if based on this study).
For dogs and cynomolgus monkeys, we can adopt the following criteria.
1. For all animals in a study, calculate the individual maximum untreated level (IULmax), the individual minimum untreated level (IULmin), and individual untreated range (IULrange; IULmax − IULmin), based on measurements Table 3 (continued)   CM01 513  457  633  847  707  999  1045 790  CM02 241  447  497  640  740  904  1207 532  CM03 365  495  623  656  899  782  717  579  CM04 618  455  349  733  298  377  341  253  CM05 241  199  298  454  291  441  331  260  CM06 281  355  684  711  407  469  833  327  CM07 298  303  465  581  687  892  990  537  CM08 262  293  403  374  360  513  619  367  CM09 354  343  419  637  508  545  679  372  CM10 236  244  273  544  288  524  345  342  Mean 341  359  464  618  519  645  711  436  SD  122  96  137  130  212  214  296 295  387  420  476  421  405  461  CF04 454  636  792  876  962  1462 1053 816  CF05 231  247  258  268  268  299  271  253  CF06 326  288  313  444  352  378  406  306  CF07 331  359  547  627  670  595  564  377  CF08 306  286  285  312  340  448  406  351  CF09 282  468  563  797  772  1011 1038 623  CF10 186  203  298  251  272  289  282  232  Mean 325  328  410  480  494  606  535  401  SD  109  124  165  206  220  360  273 For example, considering Table 3 as data of control animals, CoL and CoV are defined as 0.26 ng/mL (IULmax of CM04 at 0.5 h) and 0.10 ng/mL (the highest IULrange; 0.26-0.16 ng/mL of CM04), respectively. We regarded BLOQ values as 0.16 ng/mL (based on the LOQ value) in this calculation, to avoid overestimating IULrange. Now, suppose that one animal showed a MV of 0.50 ng/mL at some point after treatment and its IULmin was 0.16 ng/mL. In this case, the MV is considered to have resulted from treatment, since MV (0.50 ng/mL) > CoL (0.26 ng/mL) and MV (0.50 ng/mL) − IULmin (0.16 ng/mL) > CoV (0.10 ng/mL).
These criteria could minimize false positives. However, they may not be applied in cases where a small number of animals show considerably higher baseline levels than the others, since inclusion of such animals would lead to underestimation of the treatment-related changes. In such cases, excluding outliers prior to the start of a study could minimize individual variations in baseline levels.
Regarding cTnT, the values were mostly BLOQ, more frequently than those of cTnI. This might be attributable to differences in the measurement systems used. For rats, all cTnT measurements were BLOQ, and therefore, we do not need to consider individual variation or operational effects. For dogs and cynomolgus monkeys, however, we should use the same approach with cTnI, since some animals showed levels exceeding LOQ.
In conclusion, we proposed criteria to distinguish treatmentrelated effects from individual differences and operational effects in Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys. We admit that our study lacks data from animals after treatment of myocardial infarction-inducing compounds. In the future, such positive control data would be needed and would help us establish more accurate criteria.
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